Front Street Capital Increases Enovis Holdings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 26 2026
0mins
Should l Buy ENOV?
Source: Fool
- Share Acquisition Details: On February 18, 2026, Front Street Capital Management increased its holdings in Enovis by 156,069 shares, with an estimated transaction value of $4.61 million, reflecting confidence in the stock despite a 36.5% decline over the past year.
- Quarterly Performance Highlights: Enovis reported $576 million in sales for Q4 2025, with adjusted earnings per share of $0.95, exceeding market expectations and indicating potential in its turnaround efforts, despite facing over $1 billion in non-cash goodwill impairment charges.
- Market Performance Analysis: Although Enovis's stock has underperformed over the past year, it surged 14% following the latest earnings report, signaling market recognition of its future growth potential, particularly in the reconstructive devices sector.
- Investor Focus: For long-term investors, the key question is whether organic growth in reconstructive devices can translate into sustainable free cash flow, which will determine if the current market volatility represents an entry point rather than a warning sign.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ENOV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ENOV
Wall Street analysts forecast ENOV stock price to rise
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 24.660
Low
40.00
Averages
45.25
High
50.00
Current: 24.660
Low
40.00
Averages
45.25
High
50.00
About ENOV
Enovis Corporation is a medical technology company. It is focused on developing clinically differentiated solutions by manufacturing and distributing high-quality medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. It operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative diseases. The Prevention & Recovery products are marketed under several brand names, such as DJO. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. It also operates a Enovis Growth eXcellence business system (EGX).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
The Small-Cap Comeback Could Be Beginning: Here Are Some Funds and Stocks to Consider.
- Small-company stocks gaining attention: Investors are increasingly focusing on small-company stocks as interest in artificial intelligence wanes.
- Market dynamics shifting: The shift in investor sentiment indicates a broader change in market dynamics, moving away from tech-heavy investments.
- Potential for growth: Small-company stocks are seen as having significant growth potential, attracting more capital as investors seek new opportunities.
- Economic implications: This trend may reflect changing economic conditions and investor strategies in response to market fluctuations.
See More
Enovis Corporation Reports Q4 2025 Earnings Highlights
- Revenue Growth: Enovis achieved a 6% organic revenue growth in 2025, with the Recon segment showing an impressive 8% organic growth, indicating strong market performance in the competitive medical device sector.
- Financial Performance Improvement: Q4 sales reached $576 million, up 3% year-over-year, with adjusted gross margins increasing to 61%, driven by productivity gains and supply chain synergies, reflecting significant progress in cost control and operational efficiency.
- Future Outlook: Management expects 2026 revenues to range between $2.31 billion and $2.37 billion, with organic growth projected at 4% to 6%, emphasizing continued investment in innovation and integration to support future growth.
- Cash Flow Improvement: Free cash flow turned positive at $20 million for 2025, a significant improvement from the previous year, with management expressing increased confidence in future cash flow targets, indicating positive changes in the company's financial health.
See More
Front Street Capital Increases Enovis Holdings
- Share Acquisition Details: On February 18, 2026, Front Street Capital Management increased its holdings in Enovis by 156,069 shares, with an estimated transaction value of $4.61 million, reflecting confidence in the stock despite a 36.5% decline over the past year.
- Quarterly Performance Highlights: Enovis reported $576 million in sales for Q4 2025, with adjusted earnings per share of $0.95, exceeding market expectations and indicating potential in its turnaround efforts, despite facing over $1 billion in non-cash goodwill impairment charges.
- Market Performance Analysis: Although Enovis's stock has underperformed over the past year, it surged 14% following the latest earnings report, signaling market recognition of its future growth potential, particularly in the reconstructive devices sector.
- Investor Focus: For long-term investors, the key question is whether organic growth in reconstructive devices can translate into sustainable free cash flow, which will determine if the current market volatility represents an entry point rather than a warning sign.
See More
Enovis Corporation Set to Announce Q4 Earnings on February 26
- Earnings Announcement Date: Enovis Corporation is scheduled to release its Q4 2023 earnings report on February 26 before market open, with consensus EPS estimate at $0.84, reflecting a 14.3% year-over-year decline, which may impact investor sentiment.
- Revenue Expectations: The anticipated revenue for Q4 is $582.38 million, representing a 3.8% year-over-year increase, indicating stability in the company's market position, which could attract shareholders seeking reliable investments.
- Historical Performance: Over the past two years, Enovis has beaten EPS estimates 100% of the time and 75% of revenue estimates, suggesting a strong track record that may bolster market confidence in its future performance.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen two upward revisions and one downward revision, while revenue estimates experienced no upward revisions and two downward revisions, indicating mixed market expectations regarding the company's growth potential, which could influence investor decisions.
See More
Enovis Corporation Rated 'Outperform' by Evercore ISI Despite Weak Stock Performance
- Weak Stock Performance: Enovis Corporation faced a challenging year in 2025, with its stock down 50% and hitting a 52-week low of $21.00 on January 29, 2026, indicating significant macroeconomic pressures affecting its performance.
- Analyst Rating Reaffirmed: Evercore ISI analyst Vijay Kumar reiterated an 'Outperform' rating on January 12, setting a $40 price target, acknowledging a revenue miss of about 3% below expectations but projecting an EPS beat due to higher-margin reconstructive operations.
- Optimistic Cash Flow Outlook: Evercore ISI forecasts improved cash flow for FY26, with free cash flow conversion expected to exceed 25% in Q4, suggesting a potential for stronger financial performance in the near future.
- Diversified Strategy Support: BTIG analyst Ryan Zimmerman initiated coverage on Enovis on January 6, 2026, with a 'Buy' rating and a $41 price target, reflecting confidence in the company's multi-segment orthopedic strategy despite concerns regarding scale, tariffs, and cash flow.
See More
Oversold Stocks: Travere, Hims, and Enovis Present Buying Opportunities
- Travere Drug Review Extended: The FDA has extended the review timeline for Travere Therapeutics' Filspari sNDA to April 13, causing the stock to drop approximately 23% over the past month, with an RSI of 29.7 indicating oversold conditions that may present a buying opportunity for investors.
- Hims Stock Coverage Initiated: Evercore ISI analyst initiated coverage on Hims & Hers Health with an In-Line rating and a price target of $33, despite the stock falling around 13% in the last month, with an RSI of 29.7 suggesting undervaluation that could attract investor interest.
- Enovis Buy Rating Issued: BTIG analyst assigned a Buy rating to Enovis Corp with a price target of $41, even as the stock declined about 14% in the past five days, with an RSI of 29.6 indicating oversold conditions that may offer potential rebound opportunities for investors.
- Market Trend Analysis: Benzinga Pro's charting tools indicate that trends in Hims and Enovis stocks are forming, allowing investors to leverage these oversold signals for strategic positioning and capitalize on potential market rebounds.
See More
The Small-Cap Comeback Could Be Beginning: Here Are Some Funds and Stocks to Consider.
- Small-company stocks gaining attention: Investors are increasingly focusing on small-company stocks as interest in artificial intelligence wanes.
- Market dynamics shifting: The shift in investor sentiment indicates a broader change in market dynamics, moving away from tech-heavy investments.
- Potential for growth: Small-company stocks are seen as having significant growth potential, attracting more capital as investors seek new opportunities.
- Economic implications: This trend may reflect changing economic conditions and investor strategies in response to market fluctuations.
See More
Enovis Corporation Reports Q4 2025 Earnings Highlights
- Revenue Growth: Enovis achieved a 6% organic revenue growth in 2025, with the Recon segment showing an impressive 8% organic growth, indicating strong market performance in the competitive medical device sector.
- Financial Performance Improvement: Q4 sales reached $576 million, up 3% year-over-year, with adjusted gross margins increasing to 61%, driven by productivity gains and supply chain synergies, reflecting significant progress in cost control and operational efficiency.
- Future Outlook: Management expects 2026 revenues to range between $2.31 billion and $2.37 billion, with organic growth projected at 4% to 6%, emphasizing continued investment in innovation and integration to support future growth.
- Cash Flow Improvement: Free cash flow turned positive at $20 million for 2025, a significant improvement from the previous year, with management expressing increased confidence in future cash flow targets, indicating positive changes in the company's financial health.
See More
Front Street Capital Increases Enovis Holdings
- Share Acquisition Details: On February 18, 2026, Front Street Capital Management increased its holdings in Enovis by 156,069 shares, with an estimated transaction value of $4.61 million, reflecting confidence in the stock despite a 36.5% decline over the past year.
- Quarterly Performance Highlights: Enovis reported $576 million in sales for Q4 2025, with adjusted earnings per share of $0.95, exceeding market expectations and indicating potential in its turnaround efforts, despite facing over $1 billion in non-cash goodwill impairment charges.
- Market Performance Analysis: Although Enovis's stock has underperformed over the past year, it surged 14% following the latest earnings report, signaling market recognition of its future growth potential, particularly in the reconstructive devices sector.
- Investor Focus: For long-term investors, the key question is whether organic growth in reconstructive devices can translate into sustainable free cash flow, which will determine if the current market volatility represents an entry point rather than a warning sign.
See More
Enovis Corporation Set to Announce Q4 Earnings on February 26
- Earnings Announcement Date: Enovis Corporation is scheduled to release its Q4 2023 earnings report on February 26 before market open, with consensus EPS estimate at $0.84, reflecting a 14.3% year-over-year decline, which may impact investor sentiment.
- Revenue Expectations: The anticipated revenue for Q4 is $582.38 million, representing a 3.8% year-over-year increase, indicating stability in the company's market position, which could attract shareholders seeking reliable investments.
- Historical Performance: Over the past two years, Enovis has beaten EPS estimates 100% of the time and 75% of revenue estimates, suggesting a strong track record that may bolster market confidence in its future performance.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen two upward revisions and one downward revision, while revenue estimates experienced no upward revisions and two downward revisions, indicating mixed market expectations regarding the company's growth potential, which could influence investor decisions.
See More
Enovis Corporation Rated 'Outperform' by Evercore ISI Despite Weak Stock Performance
- Weak Stock Performance: Enovis Corporation faced a challenging year in 2025, with its stock down 50% and hitting a 52-week low of $21.00 on January 29, 2026, indicating significant macroeconomic pressures affecting its performance.
- Analyst Rating Reaffirmed: Evercore ISI analyst Vijay Kumar reiterated an 'Outperform' rating on January 12, setting a $40 price target, acknowledging a revenue miss of about 3% below expectations but projecting an EPS beat due to higher-margin reconstructive operations.
- Optimistic Cash Flow Outlook: Evercore ISI forecasts improved cash flow for FY26, with free cash flow conversion expected to exceed 25% in Q4, suggesting a potential for stronger financial performance in the near future.
- Diversified Strategy Support: BTIG analyst Ryan Zimmerman initiated coverage on Enovis on January 6, 2026, with a 'Buy' rating and a $41 price target, reflecting confidence in the company's multi-segment orthopedic strategy despite concerns regarding scale, tariffs, and cash flow.
See More
Oversold Stocks: Travere, Hims, and Enovis Present Buying Opportunities
- Travere Drug Review Extended: The FDA has extended the review timeline for Travere Therapeutics' Filspari sNDA to April 13, causing the stock to drop approximately 23% over the past month, with an RSI of 29.7 indicating oversold conditions that may present a buying opportunity for investors.
- Hims Stock Coverage Initiated: Evercore ISI analyst initiated coverage on Hims & Hers Health with an In-Line rating and a price target of $33, despite the stock falling around 13% in the last month, with an RSI of 29.7 suggesting undervaluation that could attract investor interest.
- Enovis Buy Rating Issued: BTIG analyst assigned a Buy rating to Enovis Corp with a price target of $41, even as the stock declined about 14% in the past five days, with an RSI of 29.6 indicating oversold conditions that may offer potential rebound opportunities for investors.
- Market Trend Analysis: Benzinga Pro's charting tools indicate that trends in Hims and Enovis stocks are forming, allowing investors to leverage these oversold signals for strategic positioning and capitalize on potential market rebounds.
See More
